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BACKGROUND—Despite renewed focus on molecular tuberculosis (TB) diagnostics and new 
antimycobacterial agents, treatment outcomes for patients co-infected with drug-resistant TB and 
human immunodeficiency virus (HIV) remain dismal, in part due to lack of focus on medication 
adherence as part of a patient-centered continuum of care.
OBJECTIVE—To review current barriers to drug-resistant TB-HIV treatment and propose an 
alternative model to conventional approaches to treatment support.
DISCUSSION—Current national TB control programs rely heavily on directly observed therapy 
(DOT) as the centerpiece of treatment delivery and adherence support. Medication adherence and 
care for drug-resistant TB-HIV could be improved by fully implementing team-based patient-
centered care, empowering patients through counseling and support, maintaining a rights-based 
approach while acknowledging the responsibility of health care systems in providing 
comprehensive care, and prioritizing critical research gaps.
CONCLUSION—It is time to re-invent our understanding of adherence in drug-resistant TB and 
HIV by focusing attention on the complex clinical, behavioral, social, and structural needs of 
affected patients and communities.
Keywords
drug-resistant TB; HIV; medication adherence; patient-centered care
APPROXIMATELY 1.5 MILLION people are living with multidrug-resistant tuberculosis 
(MDR-TB) worldwide. While the overall TB epidemic is very slowly being brought under 
control, the number of TB patients with drug-resistant TB (DR-TB) continues to rise. In 
2013 alone, the World Health Organization (WHO) estimated that 480 000 individuals 
developed MDR-TB, an increase of 80% from 2000 estimates.1 Globally, MDR-TB is 
associated with human immunodeficiency virus (HIV) infection,2 and HIV exacerbates TB 
clinically and in terms of social impact.3 In South Africa, the epicenter of the drug-resistant 
TB-HIV syndemic, up to 80% of patients with extensively drug-resistant TB (XDR-TB) are 
HIV co-infected. Even in low HIV burden countries, the proportion of DR-TB patients with 
HIV co-infection ranges between 7% and 23%.4,5
Treatment of DR-TB in low- and middle-income settings is fraught with clinical, operational 
and social challenges. Patients with DR-TB/HIV take an average of six antimycobacterial 
medications for >18 months in addition to lifelong antiretroviral therapy (ART). Treatment 
is often centralized, and involves social marginalization, family isolation, difficult and 
painful treatment regimens, dual stigmatization, and economic loss.3,6,7 In contrast, drug-
susceptible TB is typically treated over a period of 6 months, with far fewer and far less 
toxic medications, through largely decentralized channels of care. While recent innovations 
in TB diagnostics, such as the Xpert® MTB/RIF assay (Cepheid, Sunnyvale, CA, USA), 
have enhanced MDR-TB case detection, cure rates remain appallingly low.1 Poor treatment 
outcomes have a number of potential causes. Low levels of medication adherence are 
predicted to be an important cause of treatment failure,8,9 and are strongly associated with 
failure to convert TB culture to negative during treatment.8–10
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Medication adherence in ART has been carefully studied.11 Each medication has a defined 
adherence-resistance relationship, which is a function of the potency of the medication and 
replicative capacity of drug-resistant organisms. Time on ART as well as patterns of 
treatment interruptions also influence drug resistance-induced treatment failure.11–13 In 
contrast to HIV, medication adherence in DR-TB-HIV is substantially understudied.14–18 
Preliminary research from South Africa finds that XDR-TB/HIV co-infected patients report 
significantly lower adherence to TB medications than ART.10 High ART adherence with low 
TB medication adherence may improve patient survival without improving TB treatment 
outcomes,19 and contribute to ongoing transmission.
Although the WHO has endorsed more progressive approaches, such as the International 
Standards for Tuberculosis Care,20,21 the reality is that anti-tuberculosis treatment programs 
around the world focus on directly observed therapy (DOT) as the centerpiece of treatment 
delivery and adherence support. As an isolated intervention, DOT lacks a rigorous evidence 
base and is often at odds with patient needs and preferences.3,22–24 From the health systems 
perspective, DOT programs may integrate poorly into health systems, face technical 
challenges and variability of access, and poorly address stigma.24–26 To improve adherence 
in DR-TB/HIV, there is an urgent need to evaluate patient-centered care approaches that look 
beyond DOT, in particular its conventional facility-based form. Although HIV care delivery 
can inform future advances in TB management, long-term HIV management itself requires 
paradigm shifts from centralized to decentralized, patient-focused approaches that address 
the waiting times for ART refills, improved management of medical complications, 
transportation barriers, and burden on the strained health care workforce.25
A patient-centered approach to adherence in DR-TB and HIV treatment that reflects the 
Institute of Medicine (Washington DC, USA) recommendation for ‘partnership among 
practitioners, patients, and their families (when appropriate) to ensure that decisions respect 
patients’ wants, needs, and preferences and that patients have the education and support they 
need to make decisions and participate in their own care’ is imperative.26,27 In other words, 
not only should we recognize the time, cost and quality of health care services, we should 
also consider the patient’s perspective and build on patient-provider relationships to enhance 
the humaneness of care through communication, shared decision-making and support for 
self-management. Patient-centered care has been shown to have positive effects on patient 
behavior, well-being, and treatment outcomes.28 For treatment of DR-TB and HIV, 
successful programs have included important elements of patient-centered care, including 
emphasizing patient preference; decentralized, community-based care;29 and intensive 
counseling, accompaniment,30 and support; while programs using mostly conventional 
models of care have shown poor outcomes.31
We conceptualize patient-centered care as being oriented toward addressing patients’ 
priorities, not in the sense of a menu of choices, but rather as a holistic model of health care 
delivery that considers the patient as the central figure in the process or continuum of care. A 
patient-centered approach is therefore not a one-size-fits-all solution to the multifactorial 
patient-related barriers to MDR/XDR-TB/HIV treatment adherence that have been 
identified, including high TB pill burden and adverse drug effects, lack of patient education 
and counseling, provider supervision of anti-tuberculosis treatment, inability to access care 
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in the community, and the stigma of public TB notification.3,7,10 Conversely, a patient-
centered approach is a flexible model of care that reacts to the specialized needs of 
individuals. Studies of DR-TB/HIV co-infected patients have identified HIV-specific 
services as facilitators of ART adherence, including treatment literacy counseling, patient 
involvement in care, and simpler drug regimens.3,32
Patient-centered care depends on engaging each individual patient with tailored education/
counseling, understanding their motivations, and enhancing behavioral skills within the 
context of local social, structural and cultural factors. A patient-centered approach is 
particularly critical in vulnerable and marginalized MDR-/XDR-TB patients. The current 
model of care in much of the world, which relies on a clinician to examine the MDR-
TB/HIV patient and prescribe TB medications without input from counselors, social workers 
or mental health professionals, much less patients, addresses very little of this vulnerability. 
A team-based approach that includes mental health trained providers, social work trained 
providers, and behavioral counselors who can engage with patients more directly and 
holistically, and explicitly integrates HIV and DR-TB care, allows us to think about and 
make treatment decisions that encompass the full range of clinical, socio-economic and 
structural issues confronting patients.
Patient-centered approaches recognize that comprehensive care must be provided along a 
locally contextualized continuum of services. The continuum or cascade of care for DR-
TB/HIV describes the complex, integrated steps from diagnosis to cure. In DR-TB/HIV, this 
should incorporate early TB diagnosis and drug susceptibility testing, early HIV diagnosis, 
comprehensive patient education and support, infection control, streamlined entry into co-
treatment, unimpeded access to medications, adherence support, and retention in dual care. 
For patients cured of DR-TB, the cascade should conclude with support for reintegration 
back into the community, family life, and employment. For patients with disease considered 
incurable, it must include palliative care (Figure). The decline between steps in the 
continuum represents patient attrition, and underscores the need to improve care and 
retention at each step.
In March 2015, a meeting of clinicians, behavioral and social scientists, patients, and 
activists convened at the Mailman School of Public Health, Columbia University, New York, 
NY, USA, to generate a call to action for patient-centered care in the treatment of DR-TB/
HIV. We commit to working with affected communities to improve medication adherence by 
re-inventing models of care delivery that respect and address patients’ needs. This 
commitment is based on the following principles that emerged from the 2015 symposium:
1. Patient-centered care is team-based, decentralized care that requires substantial 
investment in human resources to provide high-quality care in settings where 
patients live and work, and are connected to networks of social capital and social 
support.
2. Patient education and counseling—with the goals of patient empowerment, 
treatment literacy, accountability, and reducing stigma—should be at the heart of 
adherence support for DR-TB/HIV. Core standards in counseling and education for 
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DR-TB/HIV need to be developed, as education and DOT may have different 
meanings and are implemented differently throughout the world.
3. Public health approaches to DR-TB/HIV should be based on human rights and 
equity. Where public health and individual rights conflict—for example, the 
forcible detention or isolation of people with infectious XDR-TB to protect others 
from transmission—a rights-based approach will use deliberation in accordance 
with the Siracusa Principles33 to justify rights-limiting public health measures.
4. Patient-centered care does not mean centering all responsibility on the person with 
TB. Grounding patient-centered care in rights-based approaches recognizes that 
governments and health systems must bear the responsibility to respect, protect, 
and fulfill the right to health along the cascade of care.
5. There are critical research gaps in understanding the cascade of care for DR-TB/
HIV, including biomedical, behavioral, and implementation science components. 
This research agenda must be urgently prioritized in parallel with operationalizing 
patient-centered practices, and donors should commit to funding this research.
The development of new TB diagnostics, drugs, and treatment regimens presents exciting 
opportunities to improve outcomes and reduce community transmission of DR-TB. With 
innovative and effective approaches to patient-centered care, the opportunity to impact the 
epidemic afforded by new diagnostics and drugs may not be realized. It is time for 
clinicians, researchers and TB practitioners to re-invent the understanding of adherence in 
DR-TB/HIV to eliminate disease and stigma by focusing efforts and attention on affected 
patients and communities.
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The continuum of DR-TB/HIV care defines the processes and linkages that comprise 
optimal care for MDR-/XDR-TB/HIV. The y-axis represents patients retained in care; the x-
axis represents the stages of the continuum; the arrows represent the linkages in the 
continuum. The box below defines tasks and processes that occur at each stage. TB = 
tuberculosis; HIV = human immunodeficiency virus; DR-TB = drug-resistant TB; VL = 
viral load; DST = drug susceptibility testing; MDR-TB = multidrug-resistant TB; XDR-TB 
= extensively drug-resistant TB. This image can be viewed online in colour at http://
www.ingentaconnect.com/content/iuatld/ijtld/2016/00000020/00000004/art00004
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